Libardo Torres’ Post

June is #PTSDAwarenessMonth and it's crucial to spread the word that treatments can significantly improve quality of life. Our expertise and innovative technology help study teams recognize, diagnose, and assess changes in PTSD patients. Learn more: https://hubs.li/Q02CP7_w0 

MDMA IS NEARING FDA APPROVAL - HERE IS A REVIEW OF THE TWO PIVOTAL TRIALS: Sooo exciting - MDMA is poised to become FDA's first approved psychedelic approved along with psychotherapy. We clinicians should know the studies supporting this indication inside out. In this video, Katia Zalkind and I discuss both of these studies and highlight the key findings from them. It's best to get prepared now for this major shift in psychiatric practice - and the first place to start is always knowing the data. Please enjoy our video! https://lnkd.in/gmFrpK2u

Psychedelic assisted therapies (PAT) for conditions like depression, PTSD, and substance use disorders are all over the internet and in the media spotlight. But are they right for your patients? And how would you offer them? This session at #NPInstitute2024 will discuss the model of PAT as it exists right now in the research world, examine the evidence and neuroscience behind the studies, and discuss how and when these treatments might be a part of your clinical practice. Don't wait to register - rates increase Friday! https://bit.ly/3Sd1bfw

Revolutionizing PTSD Treatment: #Vibe's Unique Diagnostic Approach 🌐 Explore the pioneering technology behind Vibe, which serves as both a therapeutic and diagnostic tool. The video delves into the science of using two frequencies simultaneously for targeted treatment and diagnosis, particularly highlighting its effectiveness in managing and understanding conditions like PTSD. It will also discuss the broader implications of this technology in reshaping traditional approaches to health care. #HealthTechLeadership #pocketpemf #ClinicalInnovation

The Aftercare Program strides to aid in the recovery of those with schizophrenia and other psychotic disorders. While we implement a number of techniques for patient improvement, including cognitive training and exercise, we are always studying different approaches to help patients recover in a way that fits uniquely to them. Routinely, participants will be asked about their symptoms and how they are able to get along with others. As our team collects this data and tracks progress during treatment, we utilize a number of cognitive assessments remote and in-person in order to understand one’s symptoms, how their problems affect their recovery, and how our team may enhance their cognitive training to further improve their day-to-day lives. Ultimately, we are determined to obtain a better understanding of how the brain plays a role in attention, learning, and memory in psychotic disorders. Think you have a client or patient who may benefit? Click the link below to schedule an appointment, or call 424-225-1779. #ucla #uclahealth #schizophrenia #uclaaftercare #firstepisode #recentonset #schizophreniaresearch #mentalhealthresearch #mentalhealth https://lnkd.in/g2cHK8fc

The evidence is building that neurofeedback in general, and Prism neurofeedback specifically, is effective in treating PTSD. Meet the study author and the rest of the GMH team at APA 2024 at booth #1628! Check out the data from the latest and largest meta-analysis, published in Frontiers, to learn more: https://lnkd.in/d6DFfC5K

A recent FDA expert panel meeting discussed the promise and challenges of MDMA-assisted therapy for PTSD. Here’s what we learned: 🔹Clinical trials showed significant symptom improvement for PTSD patients undergoing MDMA-assisted therapy, with benefits lasting several months post-treatment. 🔹Ethical and safety concerns emerged, including trial design flaws, lack of participant diversity, and the need for rigorous data on adverse effects. 🔹Despite encouraging data, the FDA panel voted against recommending MDMA-assisted therapy, citing the need for more comprehensive trials and safety evaluations. 🔹Veterans and supporters strongly advocated for MDMA therapy. PTSD impacts 13 million Americans, with veterans disproportionately affected. 🌟 Our Take: While the FDA's cautious stance underscores the complexity of introducing new treatments, the ongoing research holds promise. With further refinements, MDMA-assisted therapy could still become a transformative option for those battling PTSD. #mdmatherapyforptsd #psychedelictherapyforveterans #psychedelicresearch #PTSDrecovery #ptsdtreatment #ptsdsupport #veteranrecovery #psychedelicnews #psychedelicstudy

This decision is a significant moment in the evolving field of psychedelic medicine. While it's understandable that rigorous safety and efficacy standards must be met, this outcome highlights the ongoing challenges in integrating innovative treatments into mainstream healthcare. As someone who believes in the potential of alternative therapies, I hope that further research will continue to provide robust evidence on the benefits and risks of MDMA for PTSD patients. The journey to new medical breakthroughs is often complex and requires persistence from researchers, practitioners, and advocates alike. What are your thoughts on the future of psychedelic therapy?

A very comprehensive course that equips you with all the knowledge and information you need as a professional in trauma

Today marks an incredible milestone for Mindbloom — we’re celebrating 5 years since we treated our 1st client and transformed our 1st life! 🎉 Here’s what we’ve accomplished in just 5 years: 🌟Facilitated 520,000 ketamine therapy sessions (we’re now doing a session every 2 seconds!) 💡Created and proved paradigm-changing clinical outcomes for depression, anxiety, and PTSD 📊Published those outcomes in the #1 and #2 largest-ever peer-reviewed studies of psychedelic medicine 🏆Became the #1 provider of psychedelic therapy in the US 🏡Radically increased patient access by lowering costs, expanding i coverage, offering at-home care, and accelerating time to results ❤️🩹Crafted a stunning, beloved, and highly effective end-to-end psychedelic therapy product that would not exist in the world if we hadn’t built it Thank you to our clients, community, and team for being part of this journey. Here’s to the next 5 years and beyond! #mentalhealth #mentalhealthawareness #mentalhealthmatters #psychedelicmedicine #ketaminetherapy #mentalhealthrecovery